Ying Du Sells 46,389 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 46,389 shares of the business’s stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01. Following the completion of the sale, the chief executive officer now owns 479,851 shares in the company, valued at approximately $13,479,014.59. This trade represents a 8.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ying Du also recently made the following trade(s):

• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total value of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.
• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00.

Zai Lab Trading Up 2.2%

NASDAQ ZLAB opened at $28.75 on Friday. The stock has a market cap of $3.17 billion, a PE ratio of -10.38 and a beta of 1.04. Zai Lab Limited has a 12 month low of $16.01 and a 12 month high of $39.77. The company’s 50-day moving average price is $32.20 and its 200-day moving average price is $29.69.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. The business had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. As a group, sell-side analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ZLAB. GF Fund Management CO. LTD. bought a new stake in Zai Lab during the 4th quarter valued at $29,000. Pictet Asset Management Holding SA bought a new position in shares of Zai Lab during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Zai Lab during the first quarter valued at $75,000. Advisors Preferred LLC purchased a new position in shares of Zai Lab during the first quarter valued at $110,000. Finally, Barclays PLC raised its holdings in shares of Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after acquiring an additional 2,856 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ZLAB shares. Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Thursday, March 27th. JPMorgan Chase & Co. increased their price target on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Finally, Bank of America reissued a “neutral” rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.